Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the hedgehog pathway inhibitor GDC-0449 in dogs: An investigation using preclinical studies and physiologically based pharmacokinetic modeling

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1029-1038

  Wong, Harvey ^a   Theil, Frank Peter ^a   Cui, Yong ^a   Marsters Jr , James C ^a   Khojasteh, S Cyrus ^a   Vernillet, Laurent ^a   La, Hank ^a   Song, Xiling ^a   Wang, Hong ^a   Morinello, Eric J ^a   Deng, Yuzhong ^a   Hop, Cornelis E C A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N (4 CHLORO 3 (PYRIDINE 2 YL)PHENYL) 4 (METHYLSULFONYL)BENZAMIDE; ACTIVATED CARBON; ANTINEOPLASTIC AGENT; GDC 0449; PENTAGASTRIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; ANILIDE; CHARCOAL; PYRIDINE DERIVATIVE; VISMODEGIB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL STUDY; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INTESTINE; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE TRANSPORT; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG INTERACTION; DRUG SCREENING; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SOLUBILITY;

CANIS FAMILIARIS; ERINACEIDAE;

ADMINISTRATION, ORAL; ANILIDES; ANIMALS; CHARCOAL; COMPUTER SIMULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HEDGEHOG PROTEINS; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; PARTICLE SIZE; PYRIDINES; SOLUBILITY;

EID: 77953729581     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032680     Document Type: Article

References (28)

1. Agoram B, Woltosz WS, and Bolger MB (2001) Predicting the impact of physiological and biochemical processes on oral bioavailability. Adv Drug Rev 50:S41-S67.
2. Amidon GE, Higuchi WI, and Ho NF (1982) Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci 71:77-84.
3. Borzillo GV and Lippa B (2005) The Hedgehog signaling pathway as a target for anticancer drug discovery. Curr Top Med Chem 5:147-157.
4. Dahan A, Miller JM, and Amidon GL (2009) Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J 11:740-746.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
6. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, and Warmuth M (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944-951.
7. Ding X, Chou B, Graham RA, Cheeti S, Percey S, Matassa LC, Reuschel SA, Meng M, Liu S, Voelker T, Lum BL, Rudewicz PJ, and Hop CE (2010) Determination of GDC-0449, a small molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:785-790.
8. Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, Laciak R, Gipp J, Shaw A, Lamm ML, Munoz A, Lipinski R, Thrasher JB, and Bushman W (2004) Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145:3961-3970.
9. Ferraris RP, Lee PP, and Diamond JM (1989) Origin of regional and species differences in intestinal glucose uptake. Am J Physiol 257:G689-G697.
10. Gilbaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel Dekker Inc., New York.
11. Hahn H, Christiansen J, Wicking C, Zaphiropoulos PG, Chidambaram A, Gerrard B, Vorechovsky I, Bale AE, Toftgard R, Dean M, and Wainwright B (1996) A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. J Biol Chem 271:12125-12128.
12. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, Quinn AG, Myers RM, Cox DR, Epstein EH Jr, and Scott MP (1996) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272:1668-1671. (Pubitemid 26200029)
13. Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KL (1999) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644. (Pubitemid 29252436)
14. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
15. Parrott N, Lukacova V, Fraczkiewicz G, and Bolger MB (2009) Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects. AAPS J 11:45-53.
16. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sörensen N, Berthold F, Henk B, Schmandt N, Wolf HK, von Deimling A, Wainwright B, Chenevix-Trench G, Wiestler OD, and Wicking C (1997) Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 57:2085-2088. (Pubitemid 27247016)
17. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, and James CD (1997) Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57:842-845. (Pubitemid 27098006)
18. Sagawa K, Li F, Liese R, and Sutton SC (2009) Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. J Pharm Sci 98:2494-2500.
19. Scales SJ and de Sauvage FJ (2009) Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303-312.
20. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, and Mano T (2007) Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet 22:225-254.
21. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, and Yamashita S (2008) Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res 25:2334-2344.
22. Theil FP, Guentert TW, Haddad S, and Poulin P (2003) Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29-49.
23. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, and Low JA (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172.
24. Vorechovský I, Tingby O, Hartman M, Strömberg B, Nister M, Collins VP, and Toftgård R (1997) Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 15:361-366.
25. Wong H, Chen JZ, Chou B, Halladay JS, Kenny JR, La H, Marsters JC Jr, Plise E, Rudewicz PJ, Robarge K, Shin Y, Wong S, Zhang C, and Khojasteh SC (2009) Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3- (pyridin-2-yl)phenyl)-4- (methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 39:850-861.
26. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, and de Sauvage FJ (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326:572-574.
27. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL, and de Sauvage FJ (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455:406-410.
28. Yu LX and Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125.